GDNF and Parkinson disease: Currently a GDNF gene transfer approach using adeno-associated viral vectors (AAV2-GDNF) is evaluated in open-label phase 1 trials in PD patients (NCT04167540, NCT01621581) with results indicating an acceptable safety profile of the MRI-guided putaminal infusion (Rocco et al. 2022).